Back

The predictive value of routine troponin measurements in patients treated with immune checkpoint inhibitors

13 May 2024 (09:54 - 10:03)
Organised by: Logo
Congress Presentation Part of: How to improve prognosis in cardio-oncology Cardio-Oncology HFA Premium Access Heart Failure 2024 Heart Failure Association (HFA)

About the speaker

Photo
Associate Professor Michal Laufer-Perl

Tel Aviv Sourasky Medical Center, Tel Aviv (Israel)

4 More presentations in this session

Presentation thumbnail
Cardiotoxicity in multiple myeloma patients in Hong Kong: a single-centre experience in the past decade
Doctor M. Ho (Hong Kong, HK)
Abstract Slides Video
Presentation thumbnail
Inherited cardiovascular disease mindset at cardio-oncology screening
Doctor R. Lorca (Oviedo, ES)
Abstract Slides Video
Presentation thumbnail
Soluble guanylate cyclase activator vericiguat prevents anthracycline-mediated cardiotoxicity and sarcopenia through NO-sGC-cGMP-NLRP3 pathway
Doctor N. Maurea (Naples, IT)
Abstract Slides Video
Presentation thumbnail
Fluoropyrimidine chemotherapy and the risk of death and cardiovascular events in patients with gastrointestinal cancer: a cohort study
Doctor A. Abiodun (London, GB)
Abstract Slides Video

Access the full session

Session thumbnail
How to improve prognosis in cardio-oncology
Video

The Event

Event poster

Heart Failure 2024

13 May 2024 09:54 CET
You may be interested in
thumbnail
Congress Presentation
The predictive value of baseline troponin measurements in patients treated with immune checkpoint inhibitors
thumbnail
Congress Presentation
The predictive value of follow-up troponin measurements in patients treated with immune checkpoint inhibitors
thumbnail
Congress Session
Cardio-oncology in practice

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources